The FreeStyle Libre portfolio is associated with improved clinical outcomes*Ɨ1-9, reduced resource utilization*Ɨ10-15, and cost savings‡16.
The FreeStyle Libre portfolio is associated with improved clinical outcomes*Ɨ1-9, reduced resource utilization*Ɨ10-15, and cost savings‡16.
The FreeStyle Libre portfolio brings together an ecosystem of digital tools and features that members, providers, and caregivers can rely on.
See how use of the FreeStyle Libre portfolio is associated with:
• Reduced HbA1c*†1-7,18,19
• Reduced hypoglycemic events*Ɨ8,9
• Reduced resource utilization*Ɨ10-15
• Reduced diabetes-related work absenteeism*Ɨ12,14
In 2022, the total estimated cost of diagnosed diabetes was $412.9 billion17, with 1 in 4 healthcare dollars spent on people with diabetes. Since then, the use of the FreeStyle Libre portfolio has been associated with:
• Reduction in diabetes-related hospital admissions*†14
• Reduction in hypoglycemic events*Ɨ8,9
Continuous glucose monitoring (CGM) systems are small, wearable, sensor-based systems that help members identify glycemic patterns without fingersticks§ so they can:
• Better manage diabetes*†7-9
• Experience fewer complications*†14
• Reduce diabetes-related work absenteeism*†12,14
Get the latest industry news, updates, and announcements, plus find out all there is to know about the FreeStyle Libre portfolio of products.
Product images are for illustrative purposes only. Not actual patient data.
Medicare and other payor criteria may apply. Abbott provides this information as a courtesy and does not guarantee payment or coverage.
The FreeStyle Libre 2 system and FreeStyle Libre 3 system are indicated for use in people with diabetes ages 4 and older.
FreeStyle Libre 3 Plus sensors are indicated for use in people with diabetes 2 and older.
The FreeStyle Libre 2 app and FreeStyle Libre 3 app are only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app. Use of the FreeStyle Libre 2 app or the FreeStyle Libre 3 app may require registration with LibreView.
The FreeStyle Libre 3 app and the FreeStyle Libre 3 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.
The FreeStyle Libre 2 app and the FreeStyle Libre 2 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.
The FreeStyle Libre 2 reader, app, and sensors cannot be used interchangeably with the FreeStyle Libre 3 app and sensors.
The LibreLinkUp app is only compatible with certain mobile device and operating systems. Please check http://www.librelinkup.com for more information about device compatibility before using the app. Use of the LibreLinkUp app requires registration with LibreView. LibreLinkUp is not intended to be used for dosing decisions. The user should follow instructions on the continuous glucose monitoring system. LibreLinkUp is not intended to replace self-monitoring practices as advised by a physician.
The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.
* Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore the study data is applicable to both products.
† Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore the study data is applicable to both products.
‡ Based on prescription claims for commercial patients starting FreeStyle Libre Personal CGM systems compared to competitor CGMs. Does not include Medicare, Medicaid, and uninsured patients. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
§ Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol during the first twelve hours..
References: 1. Carlson AL, et al. BMJ Open Diabetes Res Care (2022): https://doi.org/10.1136/bmjdrc-2021-002590 2. Evans M, et al. Diabetes Ther (2022): http://doi.org/10.1007/s13300-022-01253-9 3. Wright, E. Diabetes Spectr (2021): https://doi.org/10.2337/ds20-0069 4. Kroger, J. Diabetes Care (2019): https://doi.org/10.1007/s13300-019-00741-9 5. Tyndall, V. Diabetologia (2019): https://doi.org/10.1007/s00125-019-4894-1 6. Yaron, M. Diabetes Care (2019): https://doi.org/10.2337/dc18-0166 7. Campbell, F. Pediatr Diabetes (2018): https://doi.org/10.1111/pedi.12735 8. Haak, T. Diabetes Ther (2017): https://doi.org/10.1007/s13300-016-0223-6 9. Bolinder, J. The Lancet (2016): https://doi.org/10.1016/s0140-6736(16)31535-5 10. Bergenstal, R. J Endocr Soc (2021): https://doi.org/10.1210/jendso/bvab013 11. Miller E, et al. AJMC (2021): https://doi.org/10.37765/ajmc.2021.88780 12. Charleer S, et al. Diabetes Care (2020): https://doi.org/10.2337/dc19-1610 13. Deshmukh, H. Diabetes Care (2020): https://doi.org/10.2337/dc20-0738 14. Fokkert, M. BMJ Open Diabetes Res Care (2019). https://doi.org/10.1136/bmjdrc-2019-000809 15. Kerr M, et al. Poster presented at the ATTD Conference, Madrid, Spain, February 19-22, 2020. http://doi.org/10.1089/dia.2020.2525.abstracts 16. Data on file, Abbott Diabetes Care. 17. American Diabetes Association. Diabetes Care (2023): https://doi.org/10.2337/dci23-0085 18. Aronson, et al. Diabetes Obes Metab (2022): https://doi.org/10.1111/dom.14949 19. Wada, et al. BMJ Open Diabetes Research & Care (2020): https://doi.org/10.1136/bmjdrc-2019-001115
ADC-76905 v2.0
Important Safety Information
FreeStyle Libre 14 day, FreeStyle Libre 2 and FreeStyle Libre 3 systems: Failure to use FreeStyle Libre systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose reading and alarms (if enabled) do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety info.
The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without prior written authorization of Abbott Laboratories, except to identify the product or services of the company.
This website and the information contained herein is intended for use by residents of the United States.
ADC-85718 v4.0
Payer.freestylelibre.us/en is a product-specific website intended only for residents of the United States.
If you are a resident of another country, please contact your local Abbott affiliate to obtain the appropriate product information for your country of residence.
ADC-21099 v3.0 07/21
Stay connected